Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: Ranibizumab
DATE: 27/03/2024
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
